Nomura Holdings

Nomura Holdings Portfolio holdings

AUM $22B
1-Year Est. Return 10.4%
This Quarter Est. Return
1 Year Est. Return
+10.4%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$22B
AUM Growth
+$9.62B
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
1,404
New
Increased
Reduced
Closed

Top Buys

1
+$747M
2
+$475M
3
+$365M
4
PM icon
Philip Morris
PM
+$238M
5
AAPL icon
Apple
AAPL
+$238M

Top Sells

1
+$286M
2
+$281M
3
+$281M
4
EQIX icon
Equinix
EQIX
+$232M
5
PLTR icon
Palantir
PLTR
+$172M

Sector Composition

1 Technology 23.09%
2 Consumer Discretionary 20.63%
3 Industrials 9%
4 Healthcare 7.23%
5 Communication Services 6.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PII icon
1101
Polaris
PII
$3.7B
– –
-123,231
PMM
1102
Putnam Managed Municipal Income
PMM
$273M
– –
-10,000
PMT
1103
PennyMac Mortgage Investment
PMT
$1.1B
– –
0
PMO
1104
Putnam Municipal Opportunities Trust
PMO
$295M
– –
-10,000
PMX
1105
DELISTED
PIMCO Municipal Income Fund III
PMX
– –
-10,000
PRA icon
1106
ProAssurance
PRA
$1.23B
– –
-40,000
PRAX icon
1107
Praxis Precision Medicines
PRAX
$4.8B
– –
0
PRCH icon
1108
Porch Group
PRCH
$1.01B
– –
0
PRLB icon
1109
Protolabs
PRLB
$1.22B
– –
-6,176
PROP icon
1110
Prairie Operating Co
PROP
$109M
– –
-18,907
PTGX icon
1111
Protagonist Therapeutics
PTGX
$5.47B
– –
-7,416
PVH icon
1112
PVH
PVH
$3.71B
– –
0
QQQ icon
1113
Invesco QQQ Trust
QQQ
$407B
– –
0
QTWO icon
1114
Q2 Holdings
QTWO
$4.54B
– –
-22,061
QURE icon
1115
uniQure
QURE
$1.44B
– –
0
RARE icon
1116
Ultragenyx Pharmaceutical
RARE
$3.53B
– –
-5,742
RCKT icon
1117
Rocket Pharmaceuticals
RCKT
$370M
– –
-19,661
RCUS icon
1118
Arcus Biosciences
RCUS
$3.13B
– –
-15,603
RDFN
1119
DELISTED
Redfin
RDFN
– –
0
REPL icon
1120
Replimune Group
REPL
$823M
– –
0
ROIV icon
1121
Roivant Sciences
ROIV
$14.7B
– –
0
RPM icon
1122
RPM International
RPM
$13.5B
– –
-3,647
RSP icon
1123
Invesco S&P 500 Equal Weight ETF
RSP
$74.8B
– –
0
RVMD icon
1124
Revolution Medicines
RVMD
$15.2B
– –
0
RXRX icon
1125
Recursion Pharmaceuticals
RXRX
$2.54B
– –
0
43 44
45
46 47